Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.
Antiepileptics
Drug-related problem
Generic substitution
Neurology
Parkinson’s disease
Pharmacotherapy
Systematic review
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
09
10
2019
accepted:
30
03
2020
pubmed:
11
4
2020
medline:
7
2
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
Background Generic drug exchange is common practice in most healthcare systems. While generics certainly contribute to economic savings, the altered drug formulation might be associated with potential therapeutic problems. Given the narrow therapeutic windows in neurologic indications, any detrimental effect on the therapy can lead to significant consequences. Aim of the review This review aims to investigate potential problems related to a switch from brand-name to generic or from generic to generic drug products in patients with neurologic diseases. Method The review was conducted following the PICO framework and the PRISMA guidelines. MEDLINE and Scopus databases were searched for articles published in English and German language between January 1, 1995 and October 17, 2018. Studies included in this review were randomized controlled studies, reviews, systematic reviews, overviews, cohort studies and case-control studies. Studies excluded were letters, comments, authors view, congress or seminar papers and studies with a focus on economic impact or costs. Results were synthesized qualitatively. The primary outcomes were pharmacokinetic parameters such as the area under the curve (AUC), the peak serum concentration (c
Identifiants
pubmed: 32274633
doi: 10.1007/s11096-020-01023-2
pii: 10.1007/s11096-020-01023-2
doi:
Substances chimiques
Central Nervous System Agents
0
Drugs, Generic
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-417Références
Pro Generika. Generika in Zahlen: Das Jahr 2017. https://www.progenerika.de/wp-content/uploads/2018/04/Generika-in-Zahlen_Das-Jahr-2017_ES.pdf . Accessed 6 Jan 2020.
European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the investigation on bioequivalence EMA: CPMP/EWP/QWP/1401/98. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf . Accessed 6 Jan 2020.
Guideline Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations. 2019. https://www.fda.gov/media/121311/download . Accessed 6 Jan 2020.
Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43:1583–97.
pubmed: 19776300
Finnish Medicines Agency. Generic products and generic substitution. https://www.fimea.fi/web/en/for_public/generic_products_and_generic_substitution . Accessed 6 Jan 2020.
Buhmann C, Bihler M, Emich K, Hidding U, Pötter-Nerger M, Gerloff C, et al. Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism Relat Disord. 2019:51–56.
Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70:605–21.
pubmed: 20329806
pmcid: 3056509
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–26.
pubmed: 19050195
pmcid: 2713758
Kwan P, Palmini A. Association between switching antiepileptic drug products and healthcare utilization: a systematic review. Epilepsy Behav. 2017;73:166–72.
pubmed: 28641169
Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165–76.
pubmed: 16504545
Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA annual symposium proceedings 2006:359–363.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
pubmed: 25554246
pmcid: 4320440
STROBE Statement. Strengthening the reporting of observational studies in epidemiology. https://www.strobe-statement.org/index.php?id=strobe-home . Accessed 19 Mar 2019.
Critical Appraisal Skills Programme. CASP Checklists. https://casp-uk.net/casp-tools-checklists/ . Accessed 19 Mar 2019.
Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial. JAMA Neurol. 2017;74:919–26.
pubmed: 28654954
pmcid: 5710324
Bialer M, Yacobi A, Moros D, Levitt B, Houle J, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia. 1998;39:513–9.
pubmed: 9596204
Johnson E, Chang YT, Davit B, Gidal B, Krauss G. Assessing bioequivalence of generic modified-release antiepileptic drugs. Neurology. 2016;86:1597–604.
pubmed: 27016518
pmcid: 4844239
Keller G, Czerniuk P, Bertuola R, Spatz JG, Assefi AR, Di Girolamo G. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a Single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2011;33:500–5010.
pubmed: 21635995
Pahwa R, Marjama J, McGuire D, Lyons K, Zwiebel F, Silverstein P, et al. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. Mov Disord. 1996;11:427–30.
pubmed: 8813223
Piñeyro-López A, Piñeyro-Garza E, Gómez-Silva M, Reyes-Araiza R, Flores-Diego MA, Borrego-Alvarado S, et al. Bioequivalence of single 100-mg doses of two oral formulations of topiramate: an open-label, randomized-sequence, two-period crossover study in healthy adult male Mexican volunteers. Clin Ther. 2009;31:411–7.
pubmed: 19302913
Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 2016;15:365–72.
pubmed: 26875743
Rediguieri C, Zeredo J. Assessing bioequivalence of antiepileptic drugs: are the current requirements too permissive? J Pharm Pharm Sci. 2014;17:220–8.
pubmed: 24934550
Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia. 2015;56:1415–24.
pubmed: 26201987
Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springerplus. 2016;5:182.
pubmed: 27026878
pmcid: 4766158
Talati R, Scholle JM, Phung OP, Baker EL, Baker WL, Ashaye A, et al. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy. 2012;32:314–22.
pubmed: 22461121
Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2011;45:1406–15.
pubmed: 22028417
Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia. 2007;48:1825–32.
pubmed: 17850324
Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia. 2010;51:941–50.
pubmed: 20384761
Buhmann C, Bilsing A, Fuchs G, Jost W, Müngersdorf M. The, “aut idem” problem in the therapy for parkinson’s disease | Das “aut idem” Problem in der Parkinson-Therapie. Akt Neurol. 2013;40:333–7.
Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS. Generic versus branded pharmacotherapy in Parkinson’s disease: does it matter? A review. Parkinsonism Relat Disord. 2011;17:308–12.
pubmed: 21367644
Gomez-Alonso J, Kanner AM, Herranz JL, Molins A, Gil-Nagel A. Risks and benefits of generic antiepileptic drugs. Neurologist. 2008;14:S66–72.
pubmed: 19225372
Holtkamp M, Theodore WH. Generic antiepileptic drugs-safe or harmful in patients with epilepsy? Epilepsia. 2018;59:1273–81.
pubmed: 29894004
Jankovic SM, Ignjatovic Ristic D. Is bioavailability altered in generic versus brand anticonvulsants? Expert Opin Drug Metab Toxicol. 2015;11:329–32.
pubmed: 25440299
Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007;11:46–52.
pubmed: 17537678
Maliepaard M, Hekster YA, Kappelle A, van Puijenbroek EP, Elferink AJ, Welink J et al. Requirements for generic anti-epileptic medicines: a regulatory perspective. J Neurol. 2009;256:1966–71.
pubmed: 19603244
pmcid: 2780669
Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr. 2008;8:113–7.
pubmed: 18852829
pmcid: 2566607
Richens A. Impact of generic substitution of anticonvulsants on the treatment of epilepsy. CNS Drugs. 1997;8:124–33.
pubmed: 23338217
Rösche J, Paredes VB, Schmid E, Wilharm I. The use of generic drugs in the treatment of epilepsy: an update. Psychopharmakotherapie. 2017;24:193–203.
Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther. 2010;15:81–93.
pubmed: 22477799
pmcid: 3018179
Trinka E, Krämer G, Graf M. Requirements for generic antiepileptic medicines: a clinical perspective. J Neurol. 2011;258:2128–32.
pubmed: 21667222
van Paesschen W, Hauman H, Lagae L. The use of generic medication in epilepsy: a review of potential issues and challenges. Eur J Paediatr Neurol. 2009;13:87–92.
pubmed: 18790656
Generic prescribing in epilepsy. Evid Based Med. 2010;15:65–7.
Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464–9.
pubmed: 17346246
Bosak M, Slowik A, Turaj W. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. Drug Des Devel Ther. 2017;11:2287–91.
pubmed: 28814836
pmcid: 5546726
Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin. 2010;26:455–63.
pubmed: 20014974
Duh M, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology. 2009;72:2122–9.
pubmed: 19528520
Chaluvadi S, Chiang S, Tran L, Goldsmith CE, Friedman DE. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011;52:810–5.
pubmed: 21426334
pmcid: 4500114
Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia. 2011;52:1365–71.
pubmed: 21692778
Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88:347–53.
pubmed: 20631693
pmcid: 2996138
Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52:14–8.
pubmed: 26386779
Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481–5.
pubmed: 19615948
Hansen RN, Nguyen HP, Sullivan SD. Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Epilepsy Res. 2013;106:237–43.
pubmed: 23726541
Hartung D, Middleton L, Svoboda L, McGregor JC. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study. CNS Drugs. 2012;26:707–16.
pubmed: 22731934
pmcid: 3677951
Kesselheim AS, Bykov K, Gagne JJ, Wang SV, Choudhry NK. Switching generic antiepileptic drug manufacturer not linked to seizures: a case-crossover study. Neurology. 2016;87:1796–801.
pubmed: 27683844
pmcid: 5089522
Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille M-H, Latremouille-Viau D, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology. 2010;74:1566–74.
pubmed: 20393142
Lee GH, Jung DS. Brand name to generic substitution of levetiracetam in patients with epilepsy. Seizure. 2018;60:127–31.
LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70:2179–86.
pubmed: 18505997
Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL et al. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France. Eur J Clin Pharmacol. 2017;73:471–7.
pubmed: 28035437
Polard E, Nowak E, Happe A, Biraben A, Oger E. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24:1161–9.
pubmed: 26395769
Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy. 2009;29:769–74.
pubmed: 19558250
Trimboli M, Russo E, Mumoli L, Tripepi G, Fortunato F, Mastroianni G, et al. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study. Eur J Neurol. 2018;25:666–71.
pubmed: 29322654
Vari MS, Pinto F, Mencaroni E, Giudizioso G, Minetti C, La Neve A, et al. Safety of overnight switch from brand-name to generic levetiracetam. Clin Drug Investig. 2016;36:87–91.
pubmed: 26507620
Zachry WM, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia. 2009;50:493–500.
pubmed: 18616554
Bautista RED, Gonzales W, Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res. 2011;95:158–67.
pubmed: 21530177
Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71:525–30.
pubmed: 18695164
Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 2008;13:693–9.
pubmed: 18589000
Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy. Is it safe? Seizure. 1996;5:1–5.
pubmed: 8777549
Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci. 2000;27:37–43.
pubmed: 10676586
Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 2005;7:98–105.
pubmed: 15961350
Hensler K, Uhlmann C, Porschen T, Benecke R, Rösche J. Generic substitution of antiepileptic drugs: a survey of patients’ perspectives in Germany and other German-speaking countries. Epilepsy Behav. 2013;27:135–9.
pubmed: 23416284
Krämer G, Steinhoff BJ, Feucht M, Pfäfflin M, May TW. Experiences with generic drugs in epilepsy patients. Results of an internet-based questionnaire study in Germany, Austria, and Switzerland | Erfahrungen mit Generika bei Epilepsiepatienten. Ergebnisse einer Internet-basierten Befragung in Deutschland, Österreich und der Schweiz. https://www.epi.ch/wp-content/uploads/Artikel-Kraemer_3_06.pdf . Accessed 06 Jan 2020.
McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav. 2009;14:113–7.
pubmed: 18768168
Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav. 2009;14:150–3.
pubmed: 18845274
Roth Y, Neufeld MY, Blatt I, Guy-Alfandary S, Rasaby S, Ekstein D, et al.. An evaluation of pharmacist knowledge on treatment with antiepileptic drugs. Seizure. 2016;34:60–5.
pubmed: 26731337
Sakakibara M, Kido M, Kuribayashi J, Okada H, Igarashi A, Kamei H et al. Comparison of the effects of a brand-name drug and its generic drug on the quality of life of Alzheimer’s disease patients. Clin Psychopharmacol Neurosci. 2015;13:174–9.
pubmed: 26243845
pmcid: 4540047
Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004;5:995–8.
pubmed: 15582850
Chambers JA, O’Carroll RE, Dennis M, Sudlow C, Johnston M. “My doctor has changed my pills without telling me”: impact of generic medication switches in stroke survivors. J Behav Med. 2014;37:890–901.
pubmed: 24338522
Gollwitzer S, Kostev K, Hagge M, Lang J, Graf W, Hamer HM. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology. 2016;87:466–72.
pubmed: 27371490
Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013;173:202–8.
pubmed: 23277164
Nuwer MR, Browne TR, Dodson WE, Dreifuss FE, Engel J, Leppik IE, et al. Generic substitutions for antiepileptic drugs. Neurology. 1990;40:1647–51.
pubmed: 2234419
Stuhec M, Bratović N, Mrhar A. Impact of clinical pharmacist’s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: a prospective non-randomized study. Sci Rep. 2019;9(1):16856.
pubmed: 31728029
pmcid: 6856189